Can a simple blood test beat LDL cholesterol?

ApoB testing may better flag heart attack and stroke risk

A new report argues that measuring apolipoprotein B (ApoB) can outperform traditional “bad cholesterol” metrics for predicting cardiovascular events like heart attacks and strokes. The key claim is that ApoB identifies risk more accurately and remains cost-effective.

In clinical practice, many risk assessments rely on cholesterol fractions such as LDL-C. However, ApoB acts as a proxy for the number of atherogenic particles that carry cholesterol. The research summary says that by targeting ApoB rather than just cholesterol concentration, clinicians can more precisely distinguish people at higher risk.

The practical takeaway is about screening strategy. If ApoB offers a clearer signal of who is more likely to develop serious cardiovascular disease, it could help clinicians target preventive treatment earlier—especially for patients whose LDL-C results do not fully reflect their true risk.

The story frames the change as both performance and feasibility: ApoB is presented as not only more informative but also still compatible with cost constraints, implying the test could be adopted more broadly rather than remaining limited to specialized settings.

For patients, this could mean more consistent risk stratification and potentially different treatment thresholds depending on results. For health systems, it could mean revising testing protocols in routine care and risk management.

The broader significance is that cardiovascular prevention increasingly depends on selecting biomarkers that better map to the biology of atherosclerosis. ApoB, as described here, may be a step in that direction by linking lab measurements to the particle burden that contributes to plaque buildup.